Ivermectin Tablets, 3 mg brand and generic products had US sales of approximately $20 million

Senores Pharmaceuticals and Dr Reddy's Laboratories announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL Tablets of Merck Sharp and Dohme in the US market. The product will be marketed by Dr Reddy's.

“We are pleased to advance our growth by launching a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product," stated Swapnil Shah, MD, Senores Pharmaceuticals.

Ivermectin Tablets, 3 mg brand and generic products had US sales of approximately $20 million MAT for the twelve months ending in September 2024 according to IQVIA.

Senores has long-term marketing arrangements with prominent foreign and Indian pharmaceutical companies including Dr Reddy’s Laboratories, Prasco, Lannett Company, Jubilant Cadista Pharmaceuticals, Alkem Laboratories, Sun Pharmaceuticals Industries, and Cipla USA to build an extensive pipeline across diverse dosage forms and therapeutic areas.